GO:0032945 negative regulation of mononuclear cell proliferation: Immune Suppression Mechanisms, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0032945 describes any biological process that stops, prevents, or reduces the frequency, rate, or extent of mononuclear cell proliferation, including lymphocytes, monocytes, and other peripheral blood mononuclear cells.
• Endogenous suppressors such as suppressin act as negative regulators of immune cell activation and proliferation, providing a physiological brake on mononuclear cell expansion.
• Neurohormonal pathways, including glucocorticoid and catecholamine signaling, can suppress mononuclear cell proliferation and shape immune responses.
• In CAR-T cell therapy, CAR-negative T cells can influence the proliferation and function of CAR-positive cells, highlighting the importance of negative regulation in therapeutic settings.
• Metabolic and mitochondrial regulators, such as the MARCH5-MFN2 axis, can modulate the sensitivity of mononuclear cells to apoptosis and indirectly affect proliferative capacity.
• Dysregulation of negative regulation of mononuclear cell proliferation contributes to autoimmune diseases, chronic lymphocytic leukemia, and lymphoma progression.
Description
Mononuclear cell proliferation is a central feature of adaptive and innate immunity, but uncontrolled expansion can lead to autoimmunity, chronic inflammation, and hematological malignancies. The Gene Ontology term GO:0032945, negative regulation of mononuclear cell proliferation, captures the diverse mechanisms that restrain the division of mononuclear cells, including lymphocytes, monocytes, and peripheral blood mononuclear cells (PBMCs). This process is essential for maintaining immune homeostasis and preventing pathological lymphoproliferation. Understanding its molecular players has direct implications for cancer immunotherapy, transplantation, and autoimmune disease research. Recent studies have identified endogenous negative regulators such as suppressin, which inhibits immune cell activation and proliferation, as well as neurohormonal circuits that suppress PBMC proliferation through glucocorticoid and catecholamine signaling. In parallel, the tumor microenvironment and therapeutic interventions, such as CAR-T cell therapies, are influenced by the balance between positive and negative proliferative signals. This article integrates authoritative GO annotations with verified PubMed literature to provide a research-grade overview of GO:0032945, its key genes, regulatory mechanisms, and experimental models for functional studies.
negative regulation of mononuclear cell proliferation At A Glance
| GO ID | GO:0032945 |
|---|---|
| GO term | negative regulation of mononuclear cell proliferation |
| Ontology | biological_process |
| Synonym | negative regulation of PBMC proliferation; negative regulation of peripheral blood mononuclear cell proliferation |
| Major function | Suppression of the frequency, rate, or extent of mononuclear cell division |
| Cellular context | Lymphocytes, monocytes, and peripheral blood mononuclear cells |
| Key regulators | Suppressin, neurohormonal factors, CAR-negative T cells, metabolic enzymes |
| Disease relevance | Autoimmunity, chronic lymphocytic leukemia, lymphoma, transplant rejection |
What Is GO:0032945?
GO:0032945, negative regulation of mononuclear cell proliferation, is defined as any process that stops, prevents, or reduces the frequency, rate, or extent of mononuclear cell proliferation. This includes negative regulation of peripheral blood mononuclear cell (PBMC) proliferation and lymphocyte proliferation. The term encompasses both cell-intrinsic and cell-extrinsic mechanisms, such as inhibitory cytokines, checkpoint receptors, and neuroendocrine factors that suppress the division of mononuclear cells.
Why Is negative regulation of mononuclear cell proliferation Important in Cell Biology?
Negative regulation of mononuclear cell proliferation is critical for immune tolerance and for preventing excessive immune responses that underlie autoimmune diseases and hematological malignancies. It also determines the efficacy and safety of cell-based immunotherapies, as the presence of CAR-negative T cells can modulate the expansion and persistence of CAR-T cells. Moreover, endogenous suppressors such as suppressin provide a physiological brake on immune activation, and their dysregulation may contribute to chronic inflammatory conditions. Understanding this process is therefore essential for developing targeted therapies that either enhance or inhibit mononuclear cell proliferation in cancer, autoimmunity, and transplantation.
• Maintains immune homeostasis by preventing uncontrolled lymphocyte and monocyte expansion.
• Limits autoimmune responses by suppressing autoreactive mononuclear cell proliferation.
• Influences the efficacy of CAR-T cell therapies through CAR-negative T cell-mediated regulation.
• Modulates the tumor microenvironment in hematological malignancies such as multiple myeloma and lymphoma.
• Provides a mechanism for neuroendocrine-immune crosstalk via glucocorticoids and catecholamines.
• Dysregulation is linked to chronic lymphocytic leukemia progression and B-cell proliferation.
• Serves as a target for immunosuppressive drugs in transplantation and autoimmune diseases.
• Can be exploited to enhance mitochondrial fitness and sensitize cancer cells to apoptosis.
• Involves metabolic checkpoints such as GSTP1 that affect CAR-T cell proliferation and cytotoxicity.
• Regulates cytokinesis and cell division fidelity, with clinical implications for proliferative disorders.
What Happens During negative regulation of mononuclear cell proliferation?
Initiation by inhibitory signals
In simple terms: The process starts when a mononuclear cell receives a signal that tells it to stop dividing.
Negative regulation of mononuclear cell proliferation is initiated by extracellular or intracellular cues that counteract mitogenic signals. These include inhibitory cytokines, checkpoint receptor engagement, and neurohormonal factors such as glucocorticoids and catecholamines. Endogenous suppressors like suppressin directly inhibit immune cell activation and proliferation, providing a physiological brake. In CAR-T therapy, CAR-negative T cells can suppress the expansion of CAR-positive cells, illustrating a cellular mechanism of negative regulation.
Signal transduction and cell cycle arrest
In simple terms: The stop signal is relayed inside the cell, causing the cell cycle to pause or halt.
Once inhibitory signals are received, intracellular pathways are activated that lead to cell cycle arrest. This often involves upregulation of cyclin-dependent kinase inhibitors and downregulation of proliferative transcription factors. Neurohormonal immunoregulation can suppress PBMC proliferation through modulation of these pathways. Suppressin has been shown to inhibit immune cell activation, likely by interfering with early signaling events required for proliferation.
Metabolic and mitochondrial modulation
In simple terms: The cell's energy factories and metabolic state are adjusted to support the stop signal.
Metabolic reprogramming is a key component of negative regulation. The MARCH5-MFN2 axis regulates mitochondrial fusion, and targeting this axis can sensitize multiple myeloma cells to venetoclax, indirectly affecting proliferative capacity. GSTP1, a glutathione S-transferase, improves CAR-T cell proliferation and cytotoxicity, indicating that metabolic enzymes can modulate the balance between proliferation and suppression. These findings highlight the interplay between mitochondrial dynamics and mononuclear cell proliferation.
Execution of reduced proliferation
In simple terms: The cell ultimately divides less often or not at all, reducing the overall cell population.
The final outcome of negative regulation is a decrease in the frequency, rate, or extent of mononuclear cell proliferation. This can manifest as reduced thymidine incorporation, decreased cell number, or impaired clonal expansion. In chronic lymphocytic leukemia, differential regulation of B-cell proliferation by IL21 demonstrates that negative regulation can be subset-specific and context-dependent. Regulatory T cells induced by narrowband ultraviolet B exert antigen-specific immune suppression, partly by inhibiting mononuclear cell proliferation.
Key Genes Involved in GO:0032945 negative regulation of mononuclear cell proliferation
The following genes and proteins have been experimentally linked to the negative regulation of mononuclear cell proliferation, based on verified PubMed literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| Suppressin (SUPP) | Endogenous negative regulator of immune cell activation and proliferation | Studied as a physiological brake on lymphocyte expansion |
| MARCH5 | Mitochondrial E3 ubiquitin ligase regulating MFN2 and mitochondrial fusion | Targeting MARCH5-MFN2 axis sensitizes myeloma cells to venetoclax |
| MFN2 | Mitofusin 2, mediates mitochondrial fusion | Modulates mitochondrial dynamics and apoptosis sensitivity in mononuclear cells |
| GSTP1 | Glutathione S-transferase P1, detoxification and metabolic enzyme | Improves CAR-T cell proliferation and cytotoxicity in lymphoma |
| IL21 | Cytokine that differentially regulates B-cell proliferation | Context-dependent effects on CLL B-cell subsets |
| FOXP3 | Transcription factor for regulatory T cells | Induced by NB-UVB to suppress antigen-specific immune responses |
| CD4 | T helper cell co-receptor | Target of regulatory T cell-mediated suppression |
| CD8 | Cytotoxic T cell co-receptor | Effector cells whose proliferation can be negatively regulated |
| CD19 | B-cell co-receptor | CAR-T target; CAR-negative T cells modulate proliferation |
| CD3 | T cell receptor signaling component | Central to T cell activation and proliferation |
| BCL2 | Anti-apoptotic protein | Venetoclax target; MARCH5-MFN2 axis affects sensitivity |
| MCL1 | Anti-apoptotic BCL2 family member | Modulates survival and proliferation in hematological malignancies |
| NF-κB | Transcription factor driving proliferation and inflammation | Negatively regulated by suppressin and neurohormonal signals |
| mTOR | Kinase integrating nutrient and growth signals | Central regulator of mononuclear cell proliferation and its negative control |
| Cyclin D1 | Cell cycle regulator promoting G1/S transition | Downregulated during negative regulation of proliferation |
| p27Kip1 | Cyclin-dependent kinase inhibitor | Mediates cell cycle arrest in mononuclear cells |
| GZMB | Granzyme B, effector molecule in cytotoxic lymphocytes | Modulates target cell proliferation and apoptosis |
| PRF1 | Perforin, pore-forming protein in cytotoxic cells | Involved in immune suppression mechanisms |
How Is negative regulation of mononuclear cell proliferation Regulated?
Negative regulation of mononuclear cell proliferation is controlled by a network of extracellular and intracellular signals. Neurohormonal pathways, including glucocorticoids and catecholamines, suppress PBMC proliferation through receptor-mediated signaling. Endogenous suppressin provides a direct inhibitory signal that blocks immune cell activation. In the context of CAR-T therapy, CAR-negative T cells can suppress the expansion of CAR-positive cells, and this effect is influenced by the composition of the infused product. Metabolic regulators such as GSTP1 and the MARCH5-MFN2 axis modulate mitochondrial function and apoptosis sensitivity, indirectly affecting proliferative capacity. Cytokines like IL21 can either promote or inhibit B-cell proliferation depending on the subset and context, illustrating the complexity of regulatory networks. Additionally, regulatory T cells induced by NB-UVB exert antigen-specific suppression of mononuclear cell proliferation.
negative regulation of mononuclear cell proliferation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IL21 | Chronic lymphocytic leukemia | Primary CLL B-cell subsets treated with IL21 in vitro |
| MARCH5 | Multiple myeloma | Myeloma cell lines with MARCH5 knockout or overexpression |
| GSTP1 | Lymphoma / CAR-T therapy | CAR-T cells with GSTP1 overexpression or knockout |
| FOXP3 | Autoimmunity / UVB-induced immunosuppression | NB-UVB-treated mouse models and human PBMCs |
| Suppressin | Immune dysregulation | In vitro T cell activation assays with recombinant suppressin |
Chronic Lymphocytic Leukemia (CLL)
In CLL, the proliferation of malignant B cells is differentially regulated by cytokines such as IL21. Depending on the B-cell subset, IL21 can either enhance or suppress proliferation, and dysregulation of these negative regulatory mechanisms contributes to disease progression. Understanding how negative regulation fails in CLL may reveal new therapeutic targets.
Multiple Myeloma and Lymphoma
The MARCH5-MFN2 axis regulates mitochondrial fusion and apoptosis in multiple myeloma cells. Targeting this axis enhances sensitivity to venetoclax, suggesting that mitochondrial dynamics intersect with proliferative and survival signaling. In lymphoma, GSTP1 improves CAR-T cell proliferation and cytotoxicity, highlighting the importance of metabolic regulators in controlling mononuclear cell expansion.
Autoimmune and Inflammatory Diseases
Defective negative regulation of mononuclear cell proliferation can lead to autoimmunity. Neurohormonal immunoregulation, including glucocorticoid signaling, suppresses PBMC proliferation and is exploited therapeutically in autoimmune conditions. Suppressin, an endogenous negative regulator, may offer a physiological approach to dampen immune activation. Regulatory T cells induced by NB-UVB suppress antigen-specific immune responses, providing a model for antigen-specific tolerance induction.
From negative regulation of mononuclear cell proliferation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X negatively regulate mononuclear cell proliferation? | CRISPR knockout in primary T cells or Jurkat cells followed by CFSE dilution |
| Does a point mutation in gene X alter its inhibitory function? | CRISPR point mutation knock-in in cell lines, then proliferation assays |
| Does overexpression of gene X suppress proliferation? | Lentiviral overexpression in PBMCs or CAR-T cells |
| Does a tagged version of gene X localize to specific compartments? | CRISPR knock-in of FLAG or GFP tag, imaging and co-IP |
| Which genes regulate mononuclear cell proliferation in a genome-wide manner? | CRISPR library screening with proliferation readout |
| Does gene X affect mitochondrial dynamics and apoptosis? | MARCH5-MFN2 axis perturbation in myeloma cells |
How to Study the negative regulation of mononuclear cell proliferation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CFSE dilution | Cell division history | Tracking proliferation of PBMCs or T cells |
| Ki-67 staining | Proliferative index | Flow cytometric analysis of mononuclear cell subsets |
| CRISPR knockout screen | Gene essentiality for proliferation | Discovery of negative regulators |
| RNA-seq | Transcriptional changes | Identifying pathways altered during negative regulation |
| Seahorse assay | Mitochondrial respiration and glycolysis | Metabolic profiling of suppressed cells |
| Immunoblotting | Protein expression and phosphorylation | Validating signaling changes |
| Co-immunoprecipitation | Protein-protein interactions | Studying MARCH5-MFN2 axis |
| ELISPOT | Cytokine secretion | Assessing functional suppression |
Proliferation Assays
CFSE or CellTrace Violet dilution, thymidine incorporation, and MTT assays are standard methods to measure mononuclear cell proliferation. These assays can be applied to PBMCs, T cells, B cells, and cell lines after genetic perturbation.
Flow Cytometry and Immunophenotyping
Flow cytometry allows simultaneous assessment of surface markers (CD3, CD4, CD8, CD19) and intracellular proliferation markers (Ki-67). This is essential for distinguishing effects on specific mononuclear cell subsets.
CRISPR Screening and Functional Genomics
Genome-wide CRISPR knockout or activation screens coupled with proliferation readouts can identify novel negative regulators of mononuclear cell proliferation. Such screens are powerful for discovering genes like suppressin or metabolic modulators.
Mitochondrial and Metabolic Assays
Seahorse extracellular flux analysis, mitochondrial membrane potential dyes, and ATP assays can reveal metabolic changes associated with negative regulation. The MARCH5-MFN2 axis is an example of mitochondrial dynamics influencing proliferation.
How CRISPR Can Be Used to Study GO:0032945 negative regulation of mononuclear cell proliferation
Knockout
CRISPR knockout of candidate negative regulators (e.g., Suppressin, MARCH5) in mononuclear cells can reveal whether loss of function enhances proliferation. This approach is ideal for validating genes identified in screens.
Point Mutation
Introducing specific point mutations (e.g., in GSTP1 or IL21 receptor) via CRISPR base editing or HDR can dissect domain-specific functions in negative regulation of proliferation.
Knock-in
Knock-in of reporter tags (e.g., GFP, FLAG) or conditional alleles allows tracking of negative regulator expression and localization in live cells. This is useful for studying dynamic processes like cell cycle arrest.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression can test whether increased levels of a candidate gene suppress mononuclear cell proliferation. This is particularly relevant for tumor suppressors and metabolic enzymes.
How EDITGENE Supports negative regulation of mononuclear cell proliferation Research
Researchers studying negative regulation of mononuclear cell proliferation-related genes often need to determine whether a candidate gene is causally involved in suppressing or promoting cell division. EDITGENE provides a comprehensive suite of CRISPR-based services to enable precise genetic perturbations in primary mononuclear cells, cell lines, and animal models.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of mononuclear cell proliferation research.
Frequently Asked Questions About negative regulation of mononuclear cell proliferation
What is GO:0032945?
GO:0032945 is the Gene Ontology term for negative regulation of mononuclear cell proliferation, defined as any process that stops, prevents, or reduces the frequency, rate, or extent of mononuclear cell proliferation.
What genes are involved in negative regulation of mononuclear cell proliferation?
Key genes include Suppressin, MARCH5, MFN2, GSTP1, IL21, FOXP3, and metabolic regulators such as mTOR and cyclin-dependent kinase inhibitors.
How is mononuclear cell proliferation negatively regulated?
It is regulated by inhibitory cytokines, checkpoint receptors, neurohormonal factors like glucocorticoids, and endogenous suppressors such as suppressin, which block activation and cell cycle progression.
What diseases are associated with defective negative regulation of mononuclear cell proliferation?
Defective negative regulation is linked to chronic lymphocytic leukemia, multiple myeloma, lymphoma, and autoimmune diseases.
What experimental models are used to study GO:0032945?
Common models include CRISPR knockout or overexpression in primary T cells, Jurkat cells, and CAR-T cells, followed by CFSE dilution or Ki-67 staining.
How does CAR-T cell therapy relate to negative regulation of mononuclear cell proliferation?
CAR-negative T cells can suppress the proliferation of CAR-positive cells, influencing therapy efficacy and safety.
What is the role of suppressin in mononuclear cell proliferation?
Suppressin is an endogenous negative regulator that inhibits immune cell activation and proliferation, acting as a physiological brake.
Can CRISPR screening identify new negative regulators of mononuclear cell proliferation?
Yes, genome-wide CRISPR knockout or activation screens with proliferation readouts can discover novel negative regulators.
What is the role of mitochondrial dynamics in mononuclear cell proliferation?
The MARCH5-MFN2 axis regulates mitochondrial fusion and apoptosis, indirectly affecting proliferative capacity and drug sensitivity.
How can I study negative regulation of mononuclear cell proliferation in my lab?
You can use CRISPR knockout, point mutation, knock-in, or overexpression models combined with proliferation assays, flow cytometry, and metabolic profiling. EDITGENE provides these services.
Conclusion
GO:0032945, negative regulation of mononuclear cell proliferation, is a fundamental biological process that maintains immune homeostasis and prevents pathological expansion of lymphocytes and monocytes. Its dysregulation contributes to hematological malignancies, autoimmune diseases, and therapy resistance. Key regulators such as suppressin, MARCH5, GSTP1, and IL21 provide promising targets for therapeutic intervention. Advances in CRISPR-based models and functional genomics are accelerating the discovery of new negative regulators and their mechanisms. EDITGENE offers comprehensive services to support research in this field, from knockout and point mutation models to CRISPR library screening and bioinformatics.
References
- 1. Valentino I et al.. 2025. Targeting the MARCH5-MFN2 axis to enhance mitochondrial fusion and sensitize multiple myeloma cells to venetoclax.. J Transl Med 23(1):917 PMID: 40814067
- 2. Sierro-Martínez B et al.. 2025. Unveiling the influence of CAR-negative T-cells: enhancing efficacy and ensuring safety in CAR-T therapies.. J Transl Med 23(1):942 PMID: 40830482
- 3. Istvan B. 1990. Neurohormonal immunoregulation.. Endocr Pathol 1(4):197-219 PMID: 32357612
- 4. Ban EM et al.. 1994. Suppressin: an endogenous negative regulator of immune cell activation.. Immunol Res 13(1):1-9 PMID: 7897257
- 5. Xu G et al.. 2025. GSTP1 improves CAR-T cell proliferation and cytotoxicity to combat lymphoma.. Front Immunol 16:1665407 PMID: 41080608
- 6. Tormos AM et al.. 2015. Regulation of cytokinesis and its clinical significance.. Crit Rev Clin Lab Sci 52(4):159-67 PMID: 26104038
- 7. Lu CH et al.. 2026. Narrowband Ultraviolet B Induces Peripheral Regulatory T Cells to Exert Antigen-Specific Immune Suppression.. Allergy 81(2):373-387 PMID: 40847567
- 8. Ghalamfarsa G et al.. 2013. Differential regulation of B-cell proliferation by IL21 in different subsets of chronic lymphocytic leukemia.. Cytokine 62(3):439-45 PMID: 23579027
